What is a clinical trial protocol?
Clinical research is conducted according to a plan (a protocol) or an action plan. The protocol demonstrates the guidelines for conducting the trial. It illustrates what will be made in the study by explaining each essential part of it and how it is carried out. An Investigator is selected by the sponsor to conduct a clinical trial. An Investigator should be qualified but they don’t necessarily need to be a physician, although a medical professional should be listed as a ‘sub-investigator if that is the case.
Roles and Responsibilities in Clinical Trials of Investigator, Study Coordinator, Sponsor, Monitor, a Contract research organization.
The clinical trial, definition, description, Different types of clinical trials, phases of clinical trial.
The clinical trial study team.
Requirements of the clinical trial study team.
Clinical research team role.
GCP- Good clinical practices.
Roles and Responsibilities in Clinical Trials of Investigator, Study Coordinator, Sponsor, Monitor, a Contract research organization.
The clinical trial, definition, description, Different types of clinical trials, phases of clinical trial.
The clinical trial study team.
Requirements of the clinical trial study team.
Clinical research team role.
GCP- Good clinical practices.
This document describes the detailed information of clinical trial protocol and protocol design. The protocol includes the key information of study designs. This document is downloaded as a PDF and viewed online.
SDTM Training for personnel with Junior and Intermediate level Clinical Trial Experience. Covers summary of most domains. Salient features include order of domain creation, importance of making programming Data/Metadata Driven, Nature of Clinical Raw Data, Summary of the Clinical Trial process with regards to the data flow to arrive at the Study data to be submitted to regulatory authorities like FDA, Importance of deriving ADAM from SDTM and not directly from raw data, Information has been put together from variety of sources including my own programming work.
Clinical study on human subjects according to all guidelines to form a ideal protocol and requirement to conduct clinical trial with very efficient way mainly considering to India and ICH associated countries
National programmes related to Pharmacovigilance Nitin Kale.pptxNitinKale46
Establishment of national pharmacovigilance systemsfor the reporting of adverse events, including nationaland, if appropriate, regional pharmacovigilance centres. Development of legislation/regulation for medicinemonitoring. National policy development (to include costing,budgeting and financing). The Pharmacovigilance Programme of India (PvPI) was operationalized in July 2010 by the Ministry of Health and Family Welfare, Government of India with the mission to safeguard the health of Indian population by ensuring that the benefits of use of medicine outweigh the risks associated with its use.
journal club presentation on effect of vindoline on hyperglycemia and liver...NitinKale46
vindoline effectively ameliorated diabetes induced hepatotoxicity by docking oxidative oxidative stress, inflammation and hyperglycemia in type 2 diabetes rat
More Related Content
Similar to clinical protocol & investigator information.pptx by Nitin Kale
This document describes the detailed information of clinical trial protocol and protocol design. The protocol includes the key information of study designs. This document is downloaded as a PDF and viewed online.
SDTM Training for personnel with Junior and Intermediate level Clinical Trial Experience. Covers summary of most domains. Salient features include order of domain creation, importance of making programming Data/Metadata Driven, Nature of Clinical Raw Data, Summary of the Clinical Trial process with regards to the data flow to arrive at the Study data to be submitted to regulatory authorities like FDA, Importance of deriving ADAM from SDTM and not directly from raw data, Information has been put together from variety of sources including my own programming work.
Clinical study on human subjects according to all guidelines to form a ideal protocol and requirement to conduct clinical trial with very efficient way mainly considering to India and ICH associated countries
Similar to clinical protocol & investigator information.pptx by Nitin Kale (20)
National programmes related to Pharmacovigilance Nitin Kale.pptxNitinKale46
Establishment of national pharmacovigilance systemsfor the reporting of adverse events, including nationaland, if appropriate, regional pharmacovigilance centres. Development of legislation/regulation for medicinemonitoring. National policy development (to include costing,budgeting and financing). The Pharmacovigilance Programme of India (PvPI) was operationalized in July 2010 by the Ministry of Health and Family Welfare, Government of India with the mission to safeguard the health of Indian population by ensuring that the benefits of use of medicine outweigh the risks associated with its use.
journal club presentation on effect of vindoline on hyperglycemia and liver...NitinKale46
vindoline effectively ameliorated diabetes induced hepatotoxicity by docking oxidative oxidative stress, inflammation and hyperglycemia in type 2 diabetes rat
Research on Diabetes and hepatotoxicity in wistar rat By Nitin Kale final 24...NitinKale46
Thyroid hormone is the hormone that’s mainly responsible for controlling the speed of your body’s metabolism. In infants, thyroid hormone is critical for brain development. Your thyroid, a small, butterfly-shaped gland located at the front of your neck under your skin, makes and releases thyroid hormone. It’s a part of your endocrine system.A naturally occurring coumarin called Scopoletin (SPl) has been found to have anti-inflammatory, anti-diabetic, anti-microbial, and anti-cancer characteristics. Scopoletin has been proposed to act through the antioxidant Nrf2 pathway, the pro-inflammatory NF-B pathway, the Stat-3 pathway, the hypoxia signalling pathway, the Wnt-ꞵ signalling pathway, the Notch signalling pathway, the autophagy pathway, the hypoxia signalling pathway, and other signalling pathways, depending on the cell type, organ, experimental model, and disease studied
Thyroid hormone is the hormone that’s mainly responsible for controlling the speed of your body’s metabolism. In infants, thyroid hormone is critical for brain development. Your thyroid, a small, butterfly-shaped gland located at the front of your neck under your skin, makes and releases thyroid hormone. It’s a part of your endocrine system.
Cell signalling presentation By Nitin K (1).pptxNitinKale46
A key role in the control of Ca 2+ signals is attributed to the inositol 1,4,5-trisphosphate (IP 3) receptors (IP 3 Rs), the main Ca 2+ -release channels in the ER. IP 3 Rs can transfer Ca 2+ to the mitochondria, thereby not only stimulating core metabolic pathways but also increasing apoptosis sensitivity and inhibiting basal autophagy.
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
Richard's aventures in two entangled wonderlandsRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...University of Maribor
Slides from:
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Track: Artificial Intelligence
https://www.etran.rs/2024/en/home-english/
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...Ana Luísa Pinho
Functional Magnetic Resonance Imaging (fMRI) provides means to characterize brain activations in response to behavior. However, cognitive neuroscience has been limited to group-level effects referring to the performance of specific tasks. To obtain the functional profile of elementary cognitive mechanisms, the combination of brain responses to many tasks is required. Yet, to date, both structural atlases and parcellation-based activations do not fully account for cognitive function and still present several limitations. Further, they do not adapt overall to individual characteristics. In this talk, I will give an account of deep-behavioral phenotyping strategies, namely data-driven methods in large task-fMRI datasets, to optimize functional brain-data collection and improve inference of effects-of-interest related to mental processes. Key to this approach is the employment of fast multi-functional paradigms rich on features that can be well parametrized and, consequently, facilitate the creation of psycho-physiological constructs to be modelled with imaging data. Particular emphasis will be given to music stimuli when studying high-order cognitive mechanisms, due to their ecological nature and quality to enable complex behavior compounded by discrete entities. I will also discuss how deep-behavioral phenotyping and individualized models applied to neuroimaging data can better account for the subject-specific organization of domain-general cognitive systems in the human brain. Finally, the accumulation of functional brain signatures brings the possibility to clarify relationships among tasks and create a univocal link between brain systems and mental functions through: (1) the development of ontologies proposing an organization of cognitive processes; and (2) brain-network taxonomies describing functional specialization. To this end, tools to improve commensurability in cognitive science are necessary, such as public repositories, ontology-based platforms and automated meta-analysis tools. I will thus discuss some brain-atlasing resources currently under development, and their applicability in cognitive as well as clinical neuroscience.
Slide 1: Title Slide
Extrachromosomal Inheritance
Slide 2: Introduction to Extrachromosomal Inheritance
Definition: Extrachromosomal inheritance refers to the transmission of genetic material that is not found within the nucleus.
Key Components: Involves genes located in mitochondria, chloroplasts, and plasmids.
Slide 3: Mitochondrial Inheritance
Mitochondria: Organelles responsible for energy production.
Mitochondrial DNA (mtDNA): Circular DNA molecule found in mitochondria.
Inheritance Pattern: Maternally inherited, meaning it is passed from mothers to all their offspring.
Diseases: Examples include Leber’s hereditary optic neuropathy (LHON) and mitochondrial myopathy.
Slide 4: Chloroplast Inheritance
Chloroplasts: Organelles responsible for photosynthesis in plants.
Chloroplast DNA (cpDNA): Circular DNA molecule found in chloroplasts.
Inheritance Pattern: Often maternally inherited in most plants, but can vary in some species.
Examples: Variegation in plants, where leaf color patterns are determined by chloroplast DNA.
Slide 5: Plasmid Inheritance
Plasmids: Small, circular DNA molecules found in bacteria and some eukaryotes.
Features: Can carry antibiotic resistance genes and can be transferred between cells through processes like conjugation.
Significance: Important in biotechnology for gene cloning and genetic engineering.
Slide 6: Mechanisms of Extrachromosomal Inheritance
Non-Mendelian Patterns: Do not follow Mendel’s laws of inheritance.
Cytoplasmic Segregation: During cell division, organelles like mitochondria and chloroplasts are randomly distributed to daughter cells.
Heteroplasmy: Presence of more than one type of organellar genome within a cell, leading to variation in expression.
Slide 7: Examples of Extrachromosomal Inheritance
Four O’clock Plant (Mirabilis jalapa): Shows variegated leaves due to different cpDNA in leaf cells.
Petite Mutants in Yeast: Result from mutations in mitochondrial DNA affecting respiration.
Slide 8: Importance of Extrachromosomal Inheritance
Evolution: Provides insight into the evolution of eukaryotic cells.
Medicine: Understanding mitochondrial inheritance helps in diagnosing and treating mitochondrial diseases.
Agriculture: Chloroplast inheritance can be used in plant breeding and genetic modification.
Slide 9: Recent Research and Advances
Gene Editing: Techniques like CRISPR-Cas9 are being used to edit mitochondrial and chloroplast DNA.
Therapies: Development of mitochondrial replacement therapy (MRT) for preventing mitochondrial diseases.
Slide 10: Conclusion
Summary: Extrachromosomal inheritance involves the transmission of genetic material outside the nucleus and plays a crucial role in genetics, medicine, and biotechnology.
Future Directions: Continued research and technological advancements hold promise for new treatments and applications.
Slide 11: Questions and Discussion
Invite Audience: Open the floor for any questions or further discussion on the topic.
The ability to recreate computational results with minimal effort and actionable metrics provides a solid foundation for scientific research and software development. When people can replicate an analysis at the touch of a button using open-source software, open data, and methods to assess and compare proposals, it significantly eases verification of results, engagement with a diverse range of contributors, and progress. However, we have yet to fully achieve this; there are still many sociotechnical frictions.
Inspired by David Donoho's vision, this talk aims to revisit the three crucial pillars of frictionless reproducibility (data sharing, code sharing, and competitive challenges) with the perspective of deep software variability.
Our observation is that multiple layers — hardware, operating systems, third-party libraries, software versions, input data, compile-time options, and parameters — are subject to variability that exacerbates frictions but is also essential for achieving robust, generalizable results and fostering innovation. I will first review the literature, providing evidence of how the complex variability interactions across these layers affect qualitative and quantitative software properties, thereby complicating the reproduction and replication of scientific studies in various fields.
I will then present some software engineering and AI techniques that can support the strategic exploration of variability spaces. These include the use of abstractions and models (e.g., feature models), sampling strategies (e.g., uniform, random), cost-effective measurements (e.g., incremental build of software configurations), and dimensionality reduction methods (e.g., transfer learning, feature selection, software debloating).
I will finally argue that deep variability is both the problem and solution of frictionless reproducibility, calling the software science community to develop new methods and tools to manage variability and foster reproducibility in software systems.
Exposé invité Journées Nationales du GDR GPL 2024
Toxic effects of heavy metals : Lead and Arsenicsanjana502982
Heavy metals are naturally occuring metallic chemical elements that have relatively high density, and are toxic at even low concentrations. All toxic metals are termed as heavy metals irrespective of their atomic mass and density, eg. arsenic, lead, mercury, cadmium, thallium, chromium, etc.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...Wasswaderrick3
In this book, we use conservation of energy techniques on a fluid element to derive the Modified Bernoulli equation of flow with viscous or friction effects. We derive the general equation of flow/ velocity and then from this we derive the Pouiselle flow equation, the transition flow equation and the turbulent flow equation. In the situations where there are no viscous effects , the equation reduces to the Bernoulli equation. From experimental results, we are able to include other terms in the Bernoulli equation. We also look at cases where pressure gradients exist. We use the Modified Bernoulli equation to derive equations of flow rate for pipes of different cross sectional areas connected together. We also extend our techniques of energy conservation to a sphere falling in a viscous medium under the effect of gravity. We demonstrate Stokes equation of terminal velocity and turbulent flow equation. We look at a way of calculating the time taken for a body to fall in a viscous medium. We also look at the general equation of terminal velocity.
clinical protocol & investigator information.pptx by Nitin Kale
1. Presented by-
Mr.Nitin R. Kale
M.Pharm 1st Year
Subject: P’colgical & toxicological screening method-2
Rajarshi Shahu College Of Pharmacy, Buldana.
1/15
3. CLINICAL TRIAL
Clinical trial means a systemic study of new drugs in human being
(subject) to generate data to determine pharmacological actions,
adverse effect and safety & efficacy of new drug.
Clinical trial generate high quality data for healthcare decision
making.
In clinical trial random assignment of volunteer to control group or
group receiving the experimental therapy in optimal method.
3/15
4. TRIAL PROTOCOL
Protocol, a written predefined procedures method of conducting
experiments.
It describe the rational for the trial.
Therapeutic effect.
Types of clinical trial
phase-1
phase-2
phase-3
phase-4 (post marketing surveillance)
4/15
5. Phase 1
First stage of testing in human subjects.
Designed to acess the safety, tolerability,
pharmacokinetics,pharmacodynamics of drug.
20-25 healthy volunteers; Duration:6/12 months
The aim of phase1 trial is to determine the maximum tolerated dose(MTD)
of the new treatment.
Kinds of phase:
SAD: single ascending dose studies.
MAD: multiple ascending dose studies.
Food effect: investigate difference in absorption caused by food.
Limitations :
Trial restricted to homogeneous subjects.
6. Phase 2:
It is therapeutic exploratory trial consist of 20-300 subjects.
To confirm effectiveness, monitor side effects & further evaluate safety.
Durations: 6months to several years.
Optimum dose findings:
dose efficacy relationship
therapeutic dose regimen
duration therapy
frequency of administration
7. Phase 3:
Sponsor: expert comitee review of efficacy, safety and potential
sales.
To file new drug application with DCGI(Drug Controller General Of
India).
Expert review by DCGIs comitee.
DCGI approval.
NCE marketed phase 4 begins.
Phase 4:
Post marketing surveillance (PMS).
No fixed duration/ patient populations.
Helps to detect rare ADRs, Drug interactions and also to explore
new uses for drugs.
8. Periodic safety updates: To be submitted by the manufacturer every
6 months for two years and then annually for next two years after
marketing approval.
Harmful effects discovered may result in drug being no longer sold,
or restricted to certain uses.
Confirms the efficacy and safety profile in large populations during
practice.
Detect the unknown/ rare adverse drug reactions.
Identifications of new indications.
Reporting of ADR.
9. 1) General information
2) Objective & Justification
3) Ethical consideration
4) Study design
5) Inclusion, Exclusion & withdrawal of subjects
6) Handling of product
7) Assesment of efficacy
8) Assesment of safety
9) Statistics
10) Data handeling & managements
11) Quality control & quality assurance
12) Publication policy
13) Evaluation
14) Supplementaries & appendices
5/15
10. General information:
protocol title, protocol identifying no. & date.
Name & title of person authorised to sign the protocol.
Name, title address and contact number of investigator, which
responsible for conducting study.
Name, address and contact number of the institution.
Objective & Justification:
Aim & objective of study.
Name and description of investigational product
Description & justification for route of administrations.
Dose frequency & treatment period for the pharmaceutical
product
Reference to the literature & data that are relevant to the
study.
6/15
11. Ethical consideration:
general ethical consideration related to study.
Study design:
Description of type of study (random, comparative, blinded)
Inclusion, exclusion & withdrawal of subject:
Specification of subject including age, gender.
Handling of product:
to ensure about safe handling & storage of pharmaceutical product.
The label should be necessary contain the following information.
The word – “ for clinical study only” , Name & code number of study,
Name & contact number of investigator, Name of institutions subject
identification code.
7/15
12. Statistics:
Description of statistical method to be employed.
Procedure for managing missing data ,unused data & unauthentic data.
Assesment of efficacy:
Description of how effects are measured and record.
Description of special analysed test to be carried out.
Assesment of safety:
Procedure for eliciting reports for recording ADR/ adverse events.
Information on establishment of study code, where it will light & when how it can
be broken.
Data handeling & management:
A statement “ the investigator /institutions wil permit study related monitoring,
audits,ethics ,comitee review and regulatory inspections providing direct acess to
source data / documents.
8/15
13. Quality control & Quality assurance:
A meticulous and specified plan for various steps & procedures for
purpose of controlling and monitor the study effectively.
Specifications and instruction for anticipated deviation from protocol.
Allocation of duties and responsibility with research team and then
coordination.
Finance & Insurance:
All financial aspects of conducting and reporting a study arranged
budget mode out.
How expenditure should be distributed , e.g. payment to budget
refining express of studies, purchase for apparatus, payment for
investigator.
9/15
14. Publication policy:
A publication agreement should be described in protocol.
Evaluation:
A specified account for new response to be evaluated
Methods of computations & calculations of effects.
Description of how to deal with respect about withdrawn / out of study.
Supplements & Appendices:
Documents should be appended with protocol.
Information to study subjects and providing it.
Instructions to staff.
Description of special procedures.
10/15
15. INVESTIGATOR
INFORMATION
An investigator – a person who is responsible for conducting clinical
trial site.
If a trial is conducted by a team of individuals, then the investigator
is the responsible leader of the team and called the principle
investigator.
Investigator should be qualified, educated, trained, experienced.
Show all the up-to-date document to IRB/IEC.
Familiar with investigational products and their use.
Aware and comply GCP applied regulatory reqirements.
11/15
16. RESPONSIBILITY OF AN
INVESTIGATOR
Adequate resources :
To ensure that all the person who assiting with the trial informed
about “protocol, investigational product and trial related duties and
functions.”
To arrange adequate number of qualified staff and cacilities for the
trial.
Medical care of trial subject:
Ensure that adequate medical care will provided for any ADRs
during trial.
Informed the subjects about all the risk and health problem which
can occurred during the trial before they join the trial. 12/15
17. IRB/IEC approval:
IRB/IEC approval of protocol and informed consent form before
initiation of study.
Be familiar with any national law that may impact study design.
Funding policies and the rules.
Human tissues ( storage, use, transfer to another institutionsor
other country.
Investigatinal product:
It should be handled in appropriate manner.
Packed,label and stored in correct form.
The dose recoed should be maintained.
Includes dates, quantities, batch/serial number, unique code
numbers.
13/15
18. Informed consent of trail subject:
Obtained informed consent form from patients or parents of minor patients.
To ensure patient understand the study.
On going and interactive process between the research team and patient.
14/15